Market Intelligence, Clinical Progress, and High-Purity Reagents for IBD and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNFSF15 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFSF15 (TL1A) Recombinant Protein (ECD-Fc/Trimer). High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed with native glycosylation. Sequence verified. | View TNFSF15 Products |
| Gene Delivery | TNFSF15 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View TNFSF15 Products |
| Benchmark Ab | Anti-TNFSF15 (Sequence of Tulisokibart/RVT-3101). Recombinant positive control for assay validation. | View TNFSF15 Products |
| Validator | TNFSF15 siRNA Set. For knockdown verification and specificity controls. | View TNFSF15 Products |
| Receptor (for SPR/BLI) | TNFRSF25 (DR3) ECD-Fc Fusion. High affinity binding partner for binding kinetics. | View TNFRSF25 Products |
| Related Target: TNFRSF6B | DcR3. Decoy receptor; critical for selectivity counter-screening. | View TNFRSF6B Products |
| Related Target: TNFSF14 | LIGHT (TNFSF14). Co-stimulatory TNF superfamily member with overlapping biology. | View TNFSF14 Products |
| Related Target: IL23A | IL-23 p19. Pathway synergist for combination therapy development. | View IL23A Products |
| Related Target: TNF | TNF-alpha. Synergistic inflammatory pathway, ideal for bispecific antibody targeting. | View TNF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimeric Ligand Integrity & Proper Folding | HEK293-expressed with native glycosylation; oligomeric state monitored by SEC-HPLC. Endotoxin <1EU/ug. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno TNFSF15 ortholog proteins available with >95% purity; sequence verified by mass spec. |
| Receptor Binding Specificity & Functional Blocking | TNFRSF25 (DR3) recombinant protein and stable cell lines available for neutralization assays. Homolog panel for off-target screening. |
| Lack of Reliable Assay Controls | Clinical Benchmark Antibodies (biosimilar sequences) included for assay calibration. |
| False Positives in Functional Assays | Validated siRNA included for rigorous specificity checks. |
| High Concentration Formulation Stability | Proteins available up to 200 mg/mL for viscosity and pH-dependent binding tests. |
Live TNFSF15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFSF15 (TL1A) therapeutics is intensifying, with major players shifting focus from traditional anti-TNFs to TL1A-targeted biologics. Merck (via Prometheus acquisition, PRA023/Tulisokibart), Roche (via Telavant acquisition, RVT-3101), Teva/Sanofi (TEV-'574), and Pfizer (PF-06480605) are advancing monoclonal antibodies through Phase 2/3 for ulcerative colitis and Crohn's disease. As first-generation therapies demonstrate histologic remission, the next wave targets bispecific constructs (TL1A x TNFα, TL1A x IL-23) for deeper mucosal healing, subcutaneous formulation improvements, and fibrotic disease expansion (pulmonary fibrosis, primary sclerosing cholangitis).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Merck, Roche, Teva/Sanofi, Pfizer | Ulcerative Colitis, Crohn's Disease | Affinity binding assay using high-purity trimeric ECD and DR3 protein for epitope binning. |
| Bispecific Antibody | Emerging Biotechs | Refractory IBD, Fibrosis | Heterodimer validation; dual-target SPR kinetics (e.g., TNFSF15 + IL-23). |
| Fc-Engineered mAb | Emerging pipelines | IBD, Rheumatoid Arthritis | Stability at high concentration for subcutaneous delivery (viscosity, pH profile). |
| Cell-Based Screens | Discovery Stage Pharma | Autoimmune Diseases | Receptor activation assay using TNFRSF25 stable cell lines via lentivirus transfection. |
Key Assay Considerations for TNFSF15 Drug Development
- Trimer Conformation Dependency: TL1A functions as a homotrimer; antibodies must recognize native trimeric epitopes. HEK293-expressed protein with native glycosylation ensures proper folding and multimeric assembly.
- Receptor Selectivity: TL1A binds both DR3 (TNFRSF25) and OPG (TNFRSF11B). Best-in-class drugs require selective DR3 blockade. Competitive SPR with both receptors is recommended.
- Cross-Species Reactivity: Human and cynomolgus orthologs share >95% sequence identity; mouse ortholog ~75%. Assays need species-matched proteins for preclinical PK/PD bridging.
- Subcutaneous Formulation: High-concentration (>150 mg/mL) stability testing is critical for patient compliance. TarMart supplies concentrated proteins for viscosity and pH-dependent binding evaluation.
- Off-Target Specificity: TNF superfamily homology requires counter-screening against TNFα, LIGHT, FasL, etc. TarMart provides a homolog protein panel for selectivity verification.